Chris Ryan

Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.

Advertisement The FDA has approved rusfertide (Mimrylo) for the treatment of adult patients with polycythemia vera.

Fact checked by: Riley Kandel Advertisement The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia (ET).

JAK Inhibitor Selection in Myelofibrosis Ruxolitinib remains a go-to first choice for proliferative myelofibrosis, where platelet counts are adequate and anemia is not significant.

Key Takeaways Hepcidin modulation addresses persistent real-world failure to maintain hematocrit <45% and mitigates phlebotomy-driven iron deficiency, fatigue, and cognitive symptoms in polycythemia vera. IMPRSSION met its primary end point, reducing phlebotomy rates and median phlebotomies (baseline 5.0 to 0.0–1.5), alongside sustained hematocrit reductions and increased hepcidin. Symptom burden improved, particularly at higher dosing, as reflected by MPN-SAF-TSS changes, reinforcing a class effect seen with hepcidin-pathway agents beyond hematocrit control. INTREPID enrolls ~250 phlebotomy-dependent patients regardless of background cytoreduction, using a 32-week blinded period with primary end point of phlebotomy ineligibility from weeks 20–32. Monthly sapablursen could function as monotherapy in lower-risk disease or adjunct to cytoreductives when hematocrit remains inadequately controlled, offering a pragmatic dosing interval versus competitors. SHOW MORE

Tumor sizes reduced from treatment with VP-315 in patients with basal cell carcinoma.

Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

Key Takeaways FDA authorization covers Ameluz topical gel combined with BF-RhodoLED–based PDT for adult superficial basal cell carcinoma, positioning it as a non-surgical treatment option in dermatologic oncology. Robust efficacy was demonstrated with 66% combined clinical and histologic complete response for the main target lesion at 12 weeks versus 5% with vehicle plus PDT. Histopathologic endpoints favored active therapy, with 76% histologic clearance of the main lesion compared with 19% in the control arm. Broader lesion-level activity was observed, as complete clinical clearance across all target lesions reached 83% versus 21% with placebo plus PDT. SHOW MORE